NCT01589666已完成1 期
Safety Study of Spray-Dried Solvent/Detergent-Treated Plasma for Infusion in Healthy Volunteers
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 27
- 试验地点
- 1
- 主要终点
- Incidence of treatment-emergent SAEs
研究概览
简要总结
This study is a Phase 1, single-center, open-label, ascending dose study which will assess the safety and tolerability of 5 doses of spray-dried solvent/detergent treated plasma (Resusix®) in healthy volunteers.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Subject must provide written informed consent for participation in this study and valid contact information.
- •Subject must be a male or postmenopausal female.
- •Subject must be at least 18 years of age and not older than 55 years of age.
- •Subject must be in good general health, with no significant medical history, have no clinically significant abnormalities on physical examination at Screening, including no history or symptoms of respiratory or cardiac disease.
- •Vital signs should be within normal limits at Screening:
- •Body temperature within 97°F to 99°F
- •Heart rate 45 to 100 beats per minute (bpm)
- •Systolic blood pressure (SBP) within 90 to 140 mmHg and DBP within 50 to 90 mmHg.
- •Subject must have a normal (no clinically significant abnormality) EKG at Screening and prior to administration of Resusix
- •PR interval within 120 and 200 mm/s
- •QRS interval <120 mm/s
- •QTc interval ≤440 mm/s
- •Subject must have laboratory hematology values within following normal ranges:
- •White blood cell count (WBC): 4,500 to 11,000/mL
- •Platelet (PLT) count: 150,000 to 400,000/mL;
- •Hemoglobin (Hb): 12.5 to 15.5 g/dL;
- •Activated partial thromboplastin time (aPTT): 24.6 to 36.7 seconds;
- •Normal PT, International Normalized Ratio (INR): 0.8 to 1.2;
- •Protein C ≥90%, Protein S ≥77%;
- •Antithrombin III levels (ATIII) ≥100%.
- •Subject must have laboratory clinical chemistry values within normal range specified by the testing laboratory.
- •BMI ≤30 kg/m
- •Subject must have a negative toxicology screening panel (urine test including qualitative identification of PCP, barbiturates, THC, amphetamines, benzodiazepines, opiates, and cocaine.)
- •Subject must be a non-drinker (≤2 alcoholic beverages per week) and a non-smoker (any tobacco products within six months prior to Screening).
- •Subject must have no history of recreational (including IV) drug use (by self-declaration).
- •Subject must have the ability and willingness to attend frequent visits to the study center.
排除标准
- •Subject with lower extremity deep vein thrombosis (DVT) at Screening.
- •Subject has a history of coagulopathy or thromboembolic disease.
- •Subject has a first degree family member with history of venous thromboembolic disease <55 years of age or arterial thromboembolic disease <45 years of age.
- •Subject has documented drug allergies with well-described reactions.
- •Subject has hepatomegaly, splenomegaly, adenopathy, bruising, and/or ecchymoses identified at Screening.
- •Subject is found to have positive NAT test for HIV, HBV or HCV.
- •Subject has any murmurs, rubs, or gallops on cardiac auscultation.
- •Subject has had a previous transfusion at any time.
- •Subject is unlikely to comply with the study protocol or, in the opinion of the investigator, would not be a suitable candidate for participation in the study.
研究组 & 干预措施
Spray-dried S/D-treated plasma
Experimental
Resusix (Spray-Dried Solvent/Detergent-Treated Plasma) uses source plasma from U.S.-licensed facilities as the starting material. Source plasma donors are selected from the AB blood type, which is considered a "universal" product.
干预措施: Spray-dried S/D-treated plasma (Drug)
结局指标
主要结局
Incidence of treatment-emergent SAEs
时间窗: 12 weeks
Incidence of treatment-emergent SAEs reported for up to 12 weeks post Resusix infusion
次要结局
- Change from baseline of select coagulation factors(30 minutes post infusion)
- Incidence of AEs(12 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
1 期
A Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Anti-PD-1 Antibody (HLX10) in Combination With Avastin Biosimilar (HLX04) in Patients With Advanced Solid TumorsSolid TumorNCT03757936Shanghai Henlius Biotech30
终止
1 期
Cetuximab IRDye800 Study as an Optical Imaging Agent to Detect Cancer During Surgical ProceduresHead and Neck CancerNCT01987375Eben Rosenthal1
Unknown
1 期
A Study of Bispecific Antibody QLS31901 in Patients With Advanced or Metastatic MalignanciesAdvanced Malignant TumorNCT04954456Qilu Pharmaceutical Co., Ltd.96
招募中
1 期
A Phase 1 Study of FD-001 in Recurrent /Refractory (R/R)AML/NHL/MM/MDSAMLNHLNCT06731699Chengdu FenDi Pharmaceutical Co., Ltd.72
终止
1 期
BCMA-targeted LCAR-BCDR Cells in Patients With Relapsed/Refractory Multiple MyelomaRelapsed/Refractory Multiple MyelomaNCT05376345Shanghai Changzheng Hospital24